Home > Oncology > ASCO 2019 > Hematologic Malignancies > Daratumumab a promising treatment option for transplant-eligible multiple myeloma

Daratumumab a promising treatment option for transplant-eligible multiple myeloma

Presented By
Dr Philippe Moreau, University Hospital HĂ´tel-Dieu, France
Conference
ASCO 2019
Trial
Phase 3, CASSIOPEIA
Medical writer: Emily Kuhl, PhD Primary analyses are complete from the first phase III clinical trial to investigate whether transplant-eligible patients with newly diagnosed multiple myeloma (MM) benefit from the addition of daratumumab (DARA) to standard pretransplant treatment. The findings, presented on June 2 (Abstract 8003), suggest that induction and consolidation treatment with the anti-CD38 monoclonal antibody DARA improves response rates without compromising safety. “This is the largest phase III trial to look at the path of DARA for MM patients,” said study investigator and presenter Philippe Moreau, MD, of the University Hospital Hôtel-Dieu, France. Previous trials have supported the efficacy of DARA for significantly reducing risk of disease progression and death and improving complete remission (CR) and minimal residual disease–negative rates in relapsed/refractory MM or transplant-ineligible, newly diagnosed MM. DARA in combination wit...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on